Hikma Pharmaceuticals plc (LSE:HIK) is a FTSE 250 specialty pharmaceutical group with three divisions: Injectables, Generics (Hikma Rx) and Branded. The group reported 2025 Revenue above USD 3.3 billion and a total Dividend of 84 US cents per share for the year. In March 2026 it was demoted from the FTSE 100 to the FTSE 250 following share price weakness tied to a 2026 Margin guide that fell short of consensus. Founder's son Said Darwazah returned as Chief Executive after Riad Mishlawi stepped down in December 2025. The company has launched a USD 250 million share buyback, is investing USD 1 billion to expand US sterile injectables Manufacturing by 2030 and continues to scale Biosimilars and a contract manufacturing pipeline that includes GLP-1 work. This article reviews the latest verified updates and the factors shaping the Hikma share price for UK stocks investors.

Key Takeaways

  • Hikma Pharmaceuticals (LSE:HIK) moved from the FTSE 100 to the FTSE 250 at the March 2026 FTSE Russell quarterly review, effective 23 March 2026.
  • Group revenue exceeded USD 3.3 billion in 2025, up roughly 7%, with strong Branded growth and a softer Injectables performance.
  • The board recommended a final dividend of 48 US cents per share, taking the 2025 full-year dividend to 84 US cents per share, up 5% on 2024.
  • Founder's son Said Darwazah returned as Chief Executive in December 2025 after Riad Mishlawi stepped down by mutual agreement.
  • Hikma reiterated 2026 guidance in April: revenue growth of 2% to 4% and core operating profit of USD 720 million to USD 770 million.
  • A USD 250 million share buyback was authorised, with the first USD 125 million Tranche to run between February and June 2026.
  • The group is investing USD 1 billion by 2030 in US generic and sterile injectables manufacturing across Ohio and New Jersey.

Introduction

Hikma Pharmaceuticals plc has long been one of the more distinctive names on the London Stock Exchange. It is a UK-listed FTSE 250 constituent with a global manufacturing footprint, a top-three position in US sterile injectables and the largest pharmaceutical sales base across the Middle East and North Africa. After a difficult share price reset early in 2026, the Hikma share price is back in focus for UK stocks investors weighing how the group is balancing margin pressure in its Injectables Business against an expanding biosimilars pipeline, growing contract manufacturing work and steady cash generation in its Branded division.

This article reviews what has changed at Hikma over the past year, what the latest verified company communications say about 2026 and the structural drivers that may shape HIK on the LSE in the months ahead. It is general news commentary only and does not contain Investment advice.

Company Overview: Three Businesses, One MENA Pioneer

Hikma Pharmaceuticals is headquartered in London and operates through three reporting divisions. The Injectables business supplies generic sterile injectable medicines, with the United States as its largest market, complemented by sales in Europe and the MENA region. Hikma describes itself as a top-three US supplier of generic sterile injectables, with more than 180 injectable products in its portfolio. The Generics business, branded as Hikma Rx, supplies oral and other non-injectable generic medicines into the US market and is being repositioned to add a larger contract manufacturing component over time.

The Branded division supplies branded generics and in-licensed innovative medicines across MENA, ranging from oncology and diabetes to cardiovascular and central nervous system products. In 2025, Hikma stated that it had become the largest pharmaceutical company in MENA by sales for the first time in its history, having held the second position in 2024 and the fifth position as recently as 2020. The Darwazah family, which founded the company in Jordan in 1978, remains closely involved in strategy and Leadership.

What Happened Recently

The past six months at Hikma have featured both an unusual leadership change and a sharp share price reaction. On 15 December 2025, then Chief Executive Riad Mishlawi stepped down by mutual agreement and left the board, citing retirement, with Executive Chairman and former Chief Executive Said Darwazah taking over Chief Executive responsibilities immediately. Chief Financial Officer Khalid Nabilsi joined the board as part of the same restructuring.

Hikma published its full-year 2025 results on 26 February 2026, alongside the 2025 Annual Report. The numbers were broadly in line with prior guidance, but a softer 2026 margin outlook and an acknowledgement of operational challenges in Injectables triggered a sharp sell-off. The shares fell heavily on results day, and in March 2026 FTSE Russell confirmed Hikma's demotion from the FTSE 100 to the FTSE 250 at the close of business on 20 March 2026, effective from the open on 23 March 2026, with easyJet leaving alongside as IG Group and Lion Finance Group entered the FTSE 100.

Latest Verified Update: April 2026 Trading Statement

On 23 April 2026, Hikma issued an April trading update titled "Hikma reiterates full year 2026 guidance following encouraging start to the year". The statement confirmed that the group continues to expect 2026 revenue to grow in a range of 2% to 4% and core operating profit of USD 720 million to USD 770 million.

Within the divisions, the global Injectables business was described as having started the year well, with good Demand across geographies. Hikma Rx was performing in line with expectations, with full-year revenue expected to be broadly flat and core Operating Margin close to 20%. Branded was guided to grow revenue by 6% to 8% with a core operating margin of around 25%. The company also confirmed the strategic decision to wind down its 503B compounding business in the United States, citing a focus on core operations. Management flagged ongoing inflationary pressure in shipping, energy and insurance, but said it was confident this could be absorbed through cost discipline.

Hikma Share Price Discussion

The Hikma share price has had a turbulent six months. A reference data snapshot from the London Stock Exchange listed HIK ordinary shares of 10p at 1,455.00p, in line with levels seen earlier in the spring. More recently reported data captured by Yahoo Finance and other UK market data providers indicates the share price has traded around 1,322p to 1,373p in mid-2026 after the post-results reset, with intraday weakness of around 16% to 17% noted on the day of full-year results and during subsequent volatile sessions. Investors should consult a live London Stock Exchange or broker feed for an up-to-the-minute Hikma share price quote.

Market Capitalisation has been reported in the region of GBP 2.8 billion, with around 216 million ordinary shares of 10p in issue, according to UK retail platforms tracking HIK on the LSE. The fall from prior highs reflects a combination of company-specific guidance disappointment, sector-wide concerns about US generic drug pricing and the index demotion, which can in itself drive mechanical selling from FTSE 100 tracking funds.

FTSE 250 and UK Stocks Context

Hikma now sits within the FTSE 250 after several years in the FTSE 100. According to FTSE Russell's March 2026 quarterly index review, Hikma and easyJet were demoted from the FTSE 100, while IG Group and Lion Finance Group were promoted. Index inclusion changes are determined mechanically by ranking by full market capitalisation at a specified review date, with thresholds defined by FTSE Russell.

For UK stocks investors, the move into the FTSE 250 has practical consequences. Some FTSE 100 trackers and large-cap mandates will have reduced their HIK weighting, while FTSE 250 trackers and certain mid-cap focused funds may have added the stock. The London Stock Exchange listing remains unchanged, the ticker remains HIK, and the underlying business is unaffected by the index reassignment itself. Hikma has previously moved between the FTSE 100 and FTSE 250 over its listed history and remains one of the larger pharmaceutical groups on the FTSE 250 by revenue.

Sector Backdrop: Generics Pricing, Biosimilars and GLP-1 Manufacturing

The sector context for Hikma is multi-layered. In the United States, generic drug pricing remains under structural pressure, with a long-standing trend of low single-digit price erosion in established oral generic categories. This is partly offset for Hikma by its concentration in sterile injectables, where higher manufacturing complexity, FDA scrutiny and recurring Supply shortages support pricing stability. The United States Pharmacopeia's 2024 Annual Drug Shortages report, published in May 2025, recorded that 69% of the 98 active drug shortages were sterile injectable medicines, underlining the strategic relevance of complex injectables capacity.

Biosimilars represent a structural growth lane for Hikma. The group secured FDA approval for an ustekinumab biosimilar in the first half of 2025 and, together with partner Richter, received FDA approval in 2025 for two denosumab biosimilars referencing Prolia and Xgeva, marketed as Enoby and Xtrenbo respectively. Hikma also launched its first generic GLP-1 product in 2024 and has been developing a generic referencing Victoza, while flagging contract manufacturing work for GLP-1 partners. Management has indicated that contract manufacturing could account for around 20% of Hikma Rx sales by 2030, with a 2024 contract win with a global pharmaceutical company expected to start contributing meaningfully in 2027.

In MENA branded pharmaceuticals, Hikma benefits from being a long-established local champion with deep regulatory relationships and partnerships with global innovators. Demographic growth, expanding healthcare access in markets such as Egypt and Saudi Arabia and rising demand for oncology and diabetes treatments support a constructive sectoral backdrop, although currency Volatility and geopolitical risk are persistent considerations.

2025 Results, Dividends and 2026 Guidance

Hikma reported 2025 Group revenue above USD 3.3 billion, in line with guidance, with growth supported by the Branded segment and Hikma Rx. According to company disclosures, the Branded business grew revenue by 10% in 2025 to USD 849 million, with a core operating margin of 26.4%, exceeding the previous 6% to 7% guidance range. Performance was supported by strong contributions from oncology and diabetes products, including palbociclib and dapagliflozin.

Hikma Rx delivered transformation gains and resilient margins, while the Injectables business was the principal source of margin pressure. In the first half of 2025, Injectables core Gross Profit was down 3%, with core gross margin contracting to 46.4%, reflecting changes in product and geographic mix, including the dilutive impact of the acquired Xellia portfolio. Full-year 2025 commentary noted operational challenges in Injectables that the group has begun to address. The board recommended a final dividend of 48 US cents per share, taking the 2025 total dividend to 84 US cents per share, up 5% year on year, to be paid on 30 April 2026 with an ex-dividend date of 19 March 2026.

For 2026, Hikma is guiding to revenue growth of 2% to 4% and core operating profit of USD 720 million to USD 770 million. Branded is targeted at 6% to 8% revenue growth with around 25% core operating margin, Hikma Rx is expected to be broadly flat with a margin close to 20%, and Injectables is being repositioned with a focus on stabilising margins. Alongside the 2025 results, the board authorised a share buyback programme of up to USD 250 million, with the first tranche of up to USD 125 million instructed to Citi to be executed between 26 February 2026 and 9 June 2026.

US Injectables Shortages and the USD 1 Billion Investment

Hikma's US Injectables Franchise is the linchpin of its profit pool. Persistent shortages of sterile injectable medicines in the United States have created an environment in which complex, high-quality manufacturing capacity is structurally valuable. In June 2025, Hikma Pharmaceuticals USA announced a USD 1 billion investment by 2030 to expand domestic generic and sterile injectables R&Amp;D and manufacturing capabilities. The investment will go into the group's Ohio sites in Cleveland and Columbus and New Jersey sites in Cherry Hill and Dayton.

The company currently produces more than 12 billion finished doses annually from its US footprint. Management has positioned the investment as a response to the ongoing US drug shortage challenge and as a way to reinforce Hikma's claim to a top-three position in US generic sterile injectables. Capital deployed against this expansion should support medium-term capacity and capability, although the near-term capex profile and start-up costs are a relevant consideration for free Cash Flow.

Broker Sentiment and Market Perception

Sell-Side opinion has remained broadly constructive, despite the share price reset. Aggregated UK and international research aggregators show a consensus that leans towards positive recommendations, with most contributing analysts on the bullish side and a small minority more cautious. According to data tracked on Stockopedia, the analyst consensus 12-month price target stood at around 1,911p following the early 2026 sell-off, while Investing.com referenced an average target of around 1,916p from 11 analysts. TipRanks reported a 12-month average target of around 1,888p, and other aggregators have published higher figures.

Price targets reflect varying methodologies and dates. They are presented here as published opinions of Brokers, not as endorsements. As always, broker opinions can change, and investors should not rely on any single target. Kalkine Media UK does not provide buy, sell or hold recommendations.

Growth Catalysts to Watch

  • Biosimilars pipeline: commercial momentum behind ustekinumab and the partnered denosumab launches (Enoby and Xtrenbo) and further potential filings could become a more visible revenue lane.
  • GLP-1 exposure: Hikma is developing a generic referencing Victoza and is working on contract manufacturing for GLP-1 partners, an area of structurally strong global demand.
  • US capacity investment: the USD 1 billion expansion in Ohio and New Jersey targets higher-margin sterile injectables and supports the response to ongoing US shortages.
  • Contract manufacturing scale-up: management targets contract manufacturing at around 20% of Hikma Rx sales by 2030, with a major 2024 contract expected to ramp from 2027.
  • MENA leadership: number one position in MENA pharmaceuticals by sales offers Operating Leverage as regional healthcare spending expands and oncology and diabetes franchises grow.
  • Capital returns: a USD 250 million share buyback and a progressive dividend programme provide a direct mechanism for returning cash to shareholders.

Risks to Monitor

  • US generic pricing pressure: oral generics and parts of the injectable portfolio remain exposed to continued price erosion and competitive launches.
  • FDA inspections and quality: any adverse FDA finding at a Hikma Facility could disrupt supply, delay launches and weigh on the share price.
  • Injectables margin reset: the 2025 margin contraction in Injectables, partly driven by the Xellia integration, may take time to recover.
  • Foreign exchange exposure: a US dollar reporting currency combined with MENA and European revenue creates translation and transaction risk.
  • Geopolitical risk in MENA: regional conflict, sanctions and currency controls in markets such as Egypt and the Levant can affect demand, costs and repatriation of profits.
  • Index and flow effects: the FTSE 100 demotion may continue to influence passive flows in the short term.
  • Capex execution: the USD 1 billion US investment is a multi-year programme; execution slippage or cost overruns could pressure returns.

What to Watch Next

Several specific events should help shape sentiment on Hikma over the remainder of 2026. The August 2026 interim results will offer the first formal update on whether the 2% to 4% revenue growth and USD 720 million to USD 770 million core operating profit guidance is being delivered, alongside detail on Injectables margin trends, Branded performance in MENA and progress on the wind-down of the 503B compounding business. The second-half cadence of the USD 250 million share buyback, including the resumption beyond the initial USD 125 million tranche running into June 2026, will be relevant to capital return signalling.

Beyond reporting dates, investors will be watching the regulatory pipeline. New product approvals in biosimilars, additional GLP-1 work and any meaningful US FDA inspection outcomes can materially shift the investment narrative. Hikma's track record of new launches, with 84 new product launches and 99 approvals in 2025 across the group, indicates a high baseline of pipeline activity that is likely to continue feeding the share price story.

Conclusion

Hikma Pharmaceuticals enters mid-2026 as a transformed but resilient FTSE 250 specialty pharmaceutical group. The 2025 results, the leadership change and the FTSE 100 demotion in March 2026 have all reshaped market perception. At the same time, a USD 3.3 billion plus revenue base, leadership in MENA branded pharmaceuticals, a top-three position in US sterile injectables, a USD 250 million share buyback and a USD 1 billion US capacity programme suggest a company that is investing through cycles rather than retrenching.

For UK stocks watchers tracking HIK on the LSE, the central question is whether Hikma's medium-term levers, biosimilars, contract manufacturing including GLP-1 work, MENA growth and stabilised Injectables margins, can rebuild the operating profit base into the back half of the decade. The April 2026 trading update has so far supported management's guidance, but execution will need to follow words. As always, this is a complex pharmaceutical story with material risks alongside the opportunities, and investors should do their own research and consult a qualified financial adviser where appropriate.